Silo Pharma (SILO) entered into a non-binding Letter of Intent with Allucent to provide clinical research services for two planned Phase 1 studies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback